Compare CAPL & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPL | TBPH |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.5M | 824.9M |
| IPO Year | 2012 | 2013 |
| Metric | CAPL | TBPH |
|---|---|---|
| Price | $21.01 | $17.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | 31.0K | ★ 473.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.00% | N/A |
| EPS Growth | 96.15 | ★ 279.13 |
| EPS | 1.02 | ★ 2.06 |
| Revenue | ★ $1,869,806,000.00 | $15,386,000.00 |
| Revenue This Year | N/A | $1.04 |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | $20.58 | ★ $8.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.61 | $8.33 |
| 52 Week High | $24.53 | $21.03 |
| Indicator | CAPL | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 65.69 |
| Support Level | $20.04 | $13.41 |
| Resistance Level | $21.17 | $19.04 |
| Average True Range (ATR) | 0.50 | 0.52 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 59.80 | 99.60 |
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.